Measurement of the effectiveness of tedizolid against methicillin resistant staphylococcus aureus in vitro

Abstract

Antimicrobial resistance in pathogens possess a serious public health concern today. A global effort to keep pace with this growing problem has led to the development of new and more effective anti-infective agents. One such example, tedizolid, is a second-generation (extended-spectrum) oxazolidinone with remarkable potency against a wide range of Gram-positive pathogens. It affects bacteriostatic action by binding to 23S ribosomal RNA (rRNA) in the 50S subunit of the ribosome, thus inhibiting protein synthesis. Tedizolid exhibits higher potency than other oxazolidinones including linezolid. It has been approved for the treatment of infections by highly resistant strains like methicillin-resistant Staphylococcus aureus (MRSA).